Skip to Content Skip to Search

General Meeting

Demerger

On Monday 18 July 2022, GSK plc (“GSK” or the “Company”) separated its Consumer Healthcare business from the GSK Group to form Haleon plc (“Haleon”), an independent listed company. The separation was effected by way of a demerger (the “Demerger”) of approximately 80% of GSK’s 68% holding in the Consumer Healthcare business to GSK’s shareholders.

The Consumer Healthcare business was a joint venture between GSK and Pfizer Inc (“Pfizer”), with GSK holding a majority controlling interest of 68% and Pfizer holding 32%.

A General Meeting to approve two resolutions covering: the Demerger and the GSK Share Consolidation; and the Related Party Transactions, was held on Wednesday 6 July 2022 at 2.30pm. Both resolutions set out in the Notice of General Meeting (included in the Circular to Shareholders published on 1 June 2022) were duly passed by shareholders. Further information can be found below.

More information

Shareholders can go to https://www.shareview.co.uk/clients/gskshareholder for copies of relevant documents, frequently asked questions and other useful information. 

Result of General Meeting

The General Meeting was held on Wednesday 6 July 2022 at 2.30 p.m. (UK time) at the Sofitel London Heathrow, Terminal 5, London Heathrow Airport, TW6 2GD and was broadcast live for shareholders to join electronically.

At the General Meeting both resolutions set out in the Notice of General Meeting (included in the Circular to Shareholders (PDF - 670kb) published on 1 June 2022) were duly passed by shareholders. The full text of the two resolutions tabled at the General Meeting is contained on pages 157 to 159 of the Notice of General Meeting.

The Demerger completed on Monday 18 July 2022 and GSK shareholders received one Haleon plc share for each GSK plc share held at 6.00pm UK on Friday 15 July 2022. If you were a GSK shareholder at that time you are now a shareholder in both GSK and Haleon. Haleon is a FTSE 100 company which started trading on the LSE’s Main Market at 8.00am UK on Monday 18 July 2022.

The announcement confirming the completion of the Demerger can be found here.

Following the Demerger, on Monday 18 July 2022 GSK consolidated its share capital (“GSK Share Consolidation”). This means shareholders received 4 new GSK shares of nominal value 31 1/4 pence each for every 5 existing GSK shares of nominal value 25 pence each held at 8.00pm UK on that date.

GSK’s post-consolidated shares started trading on the LSE’s Main Market at 8.00am UK on Tuesday 19 July 2022.

The announcement confirming the completion of the Share Consolidation can be found here.

Further information can be found here.

Further information on key dates in relation to the proposed demerger of Haleon and the GSK Share Consolidation can be found on pages 13 and 14 in the Circular to Shareholders (PDF - 670kb).

Voting on both resolutions put to the General Meeting was done by way of a poll rather than by a show of hands. All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.

View the Voting/Poll results (PDF - 178kb)

Documents relating to the Demerger

Shareholders can view the Circular to Shareholders and Notice of General Meeting along with associated documents via the links below:

Shareholders can view the Prospectus in relation to the proposed admission of the Haleon plc ordinary shares along with associated documents here.

Further questions

Shareholders can go to https://www.shareview.co.uk/clients/gskshareholder for copies of relevant documents, frequently asked questions and other useful information.

Previous General Meetings

Information about our previous General Meetings is available from the General Meeting archive tab above.

General Meeting archive

Back to top